NDANASALGEL, METERED
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
NATESTO (testosterone) by Teva is androgen receptor agonists [moa]. Approved for hypogonadism, testosterone deficiency. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATESTO is a nasal gel formulation of testosterone, an androgen receptor agonist approved in 2014 for testosterone deficiency and hypogonadism. It works by binding to androgen receptors to restore physiological testosterone levels. The product is indicated for a broad range of conditions including hypogonadism, erectile dysfunction, muscle atrophy, osteoporosis, and metabolic disorders like type 2 diabetes and obesity.
$0.587MPart D
Peak7.9 years to LOENATESTO is in peak lifecycle with minimal Medicare Part D penetration ($587K spending in 2023), suggesting a niche market position with stable but modest revenue trajectory.
Mechanism of Action
Androgen Receptor Agonists
Pharmacologic Class:
Androgen
Indications (2)
Clinical Trials (20)
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
20 enrolled
Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Started Jul 2025
48 enrolled
Spinal Cord InjuriesEndothelial DysfunctionTestosterone Deficiency
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Started Mar 2025
100 enrolled
Hypogonadism, Male
Puberty, Testosterone, and Brain Development
Started Dec 2024
100 enrolled
Gender IdentityGender Dysphoria in Adolescents and AdultsHeadache+1 more
Worked on NATESTO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.